{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:49:34Z","timestamp":1789411774679,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40121-024-01102-1","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T15:40:43Z","timestamp":1735918843000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-4990","authenticated-orcid":false,"given":"Bella Devaleenal","family":"Daniel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeberk Raja","family":"Inbaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugapriya","family":"Kumaravadivelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathirvel","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Ramraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-019-0966-8","volume":"19","author":"M-G Wang","year":"2019","unstructured":"Wang M-G, Luo L, Zhang Y, Liu X, Liu L, He J-Q. Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med. 2019;19:1\u201311.","journal-title":"BMC Pulm Med"},{"key":"1102_CR2","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022."},{"key":"1102_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00487-20","author":"N Panjasawatwong","year":"2020","unstructured":"Panjasawatwong N, Wattanakul T, Hoglund RM, et al. Population pharmacokinetic properties of antituberculosis drugs in Vietnamese children with tuberculous meningitis. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.00487-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1102_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/archdischild-2020-321426","volume":"107","author":"R Ruslami","year":"2022","unstructured":"Ruslami R, Gafar F, Yunivita V, et al. Pharmacokinetics and safety\/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. Arch Dis Child. 2022;107(1):70\u20137.","journal-title":"Arch Dis Child"},{"issue":"3","key":"1102_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijantimicag.2019.06.010","volume":"54","author":"R Stemkens","year":"2019","unstructured":"Stemkens R, Litjens C, Dian S, et al. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. Int J Antimicrob Agents. 2019;54(3):371\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"1102_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000069","volume":"1","author":"PJ Dodd","year":"2021","unstructured":"Dodd PJ, Osman M, Cresswell FV, et al. The global burden of tuberculous meningitis in adults: a modelling study. PLOS Global Public Health. 2021;1(12):e0000069.","journal-title":"PLOS Global Public Health"},{"issue":"7","key":"1102_CR7","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1007\/s00415-022-11052-8","volume":"269","author":"A Navarro-Flores","year":"2022","unstructured":"Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, Soriano-Moreno DR, Pacheco-Barrios K. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. J Neurol. 2022;269(7):3482\u201394.","journal-title":"J Neurol"},{"issue":"8","key":"1102_CR8","doi-asserted-by":"publisher","first-page":"ofaa257","DOI":"10.1093\/ofid\/ofaa257","volume":"7","author":"AM Stadelman","year":"2020","unstructured":"Stadelman AM, Ellis J, Samuels TH, et al. Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis. Open Forum Infect Dis. 2020;7(8):ofaa257.","journal-title":"Open Forum Infect Dis"},{"key":"1102_CR9","doi-asserted-by":"crossref","unstructured":"Inbaraj L, Rade K, Selvaraju S, Rao R. Mortality estimates of central nervous system TB in India. Int J Tuberc Lung Dis. 2023;27(11):876\u20137.","DOI":"10.5588\/ijtld.23.0308"},{"issue":"6","key":"1102_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jac\/29.6.719","volume":"29","author":"R Nau","year":"1992","unstructured":"Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother. 1992;29(6):719\u201324.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1102_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/ajrccm\/148.3.650","volume":"148","author":"GA Ellard","year":"1993","unstructured":"Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis. 1993;148(3):650\u20135.","journal-title":"Am Rev Respir Dis"},{"key":"1102_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01014-18","author":"S Dian","year":"2018","unstructured":"Dian S, Yunivita V, Ganiem A, et al. Double-blind, randomized, placebo-controlled phase\u00a0II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.01014-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1102_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/cid\/ciab162","volume":"73","author":"FV Cresswell","year":"2021","unstructured":"Cresswell FV, Meya DB, Kagimu E, Grint D, et al. High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a phase\u00a0II open-label randomized controlled trial. Clin Infect Dis. 2021;73(5):876\u201384.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1102_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","volume":"90","author":"P Donald","year":"2010","unstructured":"Donald P. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90(5):279\u201392.","journal-title":"Tuberculosis"},{"key":"1102_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2023.102465","volume":"144","author":"V Yunivita","year":"2024","unstructured":"Yunivita V, Te Brake L, Dian S, et al. Isoniazid exposures and acetylator status in Indonesian tuberculous meningitis patients. Tuberculosis. 2024;144:102465.","journal-title":"Tuberculosis"},{"issue":"5","key":"1102_CR16","first-page":"783","volume":"99","author":"VA Place","year":"1969","unstructured":"Place VA, Pyle MM, De la Huerga J. Ethambutol in tuberculous meningitis. Am Rev Respir Dis. 1969;99(5):783\u20135.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"1102_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0041-3879(71)90017-1","volume":"52","author":"JA Pilheu","year":"1971","unstructured":"Pilheu JA, Maglio F, Cetrangolo R, Pleus AD. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle. 1971;52(2):117\u201322.","journal-title":"Tubercle"},{"key":"1102_CR18","doi-asserted-by":"crossref","unstructured":"Grosset J. The efficacy of short-course chemotherapy for tuberculosis. Bull Pan Am Health Org (PAHO). 1980;14(2):139\u201349.","DOI":"10.1016\/S0272-5231(21)00072-1"},{"issue":"2","key":"1102_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0041-3879(80)90012-4","volume":"61","author":"Third East African\/British Medical Research Council Study","year":"1980","unstructured":"Third East African\/British Medical Research Council Study. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Tubercle. 1980;61(2):59\u201369.","journal-title":"Tubercle"},{"issue":"4_pt_1","key":"1102_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1164\/ajrccm\/143.4_Pt_1.700","volume":"143","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1991","unstructured":"Hong Kong Chest Service\/British Medical Research Council. Controlled trial of 2, 4, and 6\u00a0months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30\u00a0months. Am Rev Respir Dis. 1991;143(4_pt_1):700\u20136.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"1102_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/QCO.0000000000000418","volume":"31","author":"R Nau","year":"2018","unstructured":"Nau R, Seele J, Djukic M, Eiffert H. Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. Curr Opin Infect Dis. 2018;31(1):57\u201368.","journal-title":"Curr Opin Infect Dis"},{"issue":"6567","key":"1102_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bmj.294.6567.284","volume":"294","author":"G Ellard","year":"1987","unstructured":"Ellard G, Humphries M, Gabriel M, Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J (Clin Res Ed). 1987;294(6567):284.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1102_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectrum. 2014. https:\/\/doi.org\/10.1128\/microbiolspec.MGM2-0023-2013.","journal-title":"Microbiol Spectrum"},{"issue":"1","key":"1102_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003008","volume":"17","author":"AS Dean","year":"2020","unstructured":"Dean AS, Zignol M, Cabibbe AM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008.","journal-title":"PLoS Med"},{"issue":"1","key":"1102_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jnnp.53.1.81","volume":"53","author":"P Phuapradit","year":"1990","unstructured":"Phuapradit P, Supmonchai K, Kaojarern S, Mokkhavesa C. The blood\/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J Neurol Neurosurg Psychiatry. 1990;53(1):81\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1102_CR26","doi-asserted-by":"crossref","unstructured":"Zhang N, Savic RM, Boeree MJ, et al. Optimising pyrazinamide for the treatment of tuberculosis. Eur Respir J. 2021;58(1):2002013.","DOI":"10.1183\/13993003.02013-2020"},{"key":"1102_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","volume":"60","author":"MG Sturkenboom","year":"2021","unstructured":"Sturkenboom MG, M\u00e4rtson A-G, Svensson EM, et al. Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet. 2021;60:685\u2013710.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1102_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133869","volume":"10","author":"MG Whitfield","year":"2015","unstructured":"Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS ONE. 2015;10(7):e0133869.","journal-title":"PLoS ONE"},{"key":"1102_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-3757-1","volume":"19","author":"SP Juma","year":"2019","unstructured":"Juma SP, Maro A, Pholwat S, et al. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. BMC Infect Dis. 2019;19:1\u20136.","journal-title":"BMC Infect Dis"},{"key":"1102_CR30","doi-asserted-by":"crossref","unstructured":"Chen RH, Michael T, Kuhlin J, Sch\u00f6n T, Stocker S, Alffenaar J-WC. Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review. Int J Antimicrob Agents. 2023;62:106914.","DOI":"10.1016\/j.ijantimicag.2023.106914"},{"issue":"10","key":"1102_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/archneur.1986.00520100008005","volume":"43","author":"A Pauranik","year":"1986","unstructured":"Pauranik A, Behari M, Maheshwari MC. Pyrazinamide in treatment of tuberculous meningitis. Arch Neurol. 1986;43(10):982.","journal-title":"Arch Neurol"},{"issue":"12","key":"1102_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1164\/rccm.200802-355OC","volume":"177","author":"KC Chang","year":"2008","unstructured":"Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med. 2008;177(12):1391\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1102_CR33","first-page":"679","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology. 2017;56(5):679\u201388.","journal-title":"Rheumatology"},{"issue":"2","key":"1102_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.18203\/2320-6012.ijrms20220304","volume":"10","author":"A Emorinken","year":"2022","unstructured":"Emorinken A, Ugheoke AJ. Pyrazinamide-induced acute gouty arthritis: a case report. Int J Res Med Sci. 2022;10(2):526.","journal-title":"Int J Res Med Sci"},{"key":"1102_CR35","doi-asserted-by":"crossref","unstructured":"Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 2013;57(4):1685\u201390.","DOI":"10.1128\/AAC.01866-12"},{"issue":"4","key":"1102_CR36","first-page":"154","volume":"22","author":"N Inayat","year":"2016","unstructured":"Inayat N, Shah RH, Lakhair MA, Sahito R. Hyperuricemia & arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis. Pak J Chest Med. 2016;22(4):154\u20138.","journal-title":"Pak J Chest Med"},{"issue":"3","key":"1102_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/0250-474X.159602","volume":"77","author":"JR Varma","year":"2015","unstructured":"Varma JR, Kumar TS, Prasanthi B, Ratna JV. Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: efficiency for alveolar macrophage targeting. Indian J Pharm Sci. 2015;77(3):258.","journal-title":"Indian J Pharm Sci"},{"issue":"3","key":"1102_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/INF.0000000000000065","volume":"33","author":"R van Toorn","year":"2014","unstructured":"van Toorn R, Schaaf HS, Laubscher JA, van Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33(3):248\u201352.","journal-title":"Pediatr Infect Dis J"},{"key":"1102_CR39","doi-asserted-by":"publisher","unstructured":"Sulis G, Tavaziva G, Gore G, et al. Comparative effectiveness of regimens for drug-susceptible tuberculous meningitis in children and adolescents: a systematic review and aggregate-level data meta-analysis. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofac108.","DOI":"10.1093\/ofid\/ofac108"},{"key":"1102_CR40","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. In: Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022."},{"key":"1102_CR41","doi-asserted-by":"crossref","unstructured":"Jullien S, Ryan H, Modi M, Bhatia R. Six months therapy for tuberculous meningitis. Cochrane Database Syst Rev. 2016;9(9):CD012091.","DOI":"10.1002\/14651858.CD012091.pub2"},{"issue":"1","key":"1102_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13063-024-08133-6","volume":"25","author":"LR Inbaraj","year":"2024","unstructured":"Inbaraj LR, Manesh A, Ponnuraja C, Bhaskar A, Srinivasalu VA, Daniel BD. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial). Trials. 2024;25(1):294.","journal-title":"Trials"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01102-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:56:40Z","timestamp":1739642200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01102-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (Bella Devaleenal Daniel, Leeberk Raja Inbaraj, Shanmugapriya Kumaravadivelu, Kathirvel Subramanian, Balaji Ramraj, Abi Manesh) declare that they do not have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}